Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metz, L. M.
Right arrow Articles by Meddings, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metz, L. M.
Right arrow Articles by Meddings, J. B.
Neurology 1999;53:2093
© 1999 American Academy of Neurology
Articles

Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis

L. M. Metz, MD, FRCPC, D. Sabuda, BSP, R. J. Hilsden, MD, FRCPC, R. Enns, MD, FRCPC and J. B. Meddings, MD, FRCPC

From the Departments of Clinical Neurosciences (Dr. Metz), Medicine (Drs. Enns and Meddings), and Community Health Sciences (Dr. Hilsden), University of Calgary, and Foothills Hospital (D. Sabuda), Calgary, Alberta, Canada.

Address correspondence and reprint requests to Dr. Luanne Metz, Foothills Hospital, 1403-29 St. N W, Calgary, Alberta, Canada, T2N 2T9.

BACKGROUND: Prednisone and methylprednisolone are well absorbed orally and have lower treatment costs than IV methylprednisolone, but concern that low-dose corticosteroid may cause increased disease activity and that high oral doses may cause gastric ulceration inhibits use of oral therapy for MS attacks.

METHODS: Gastric mucosal injury, detected by measurement of gastric permeability, was examined after five alternate day doses of IV methylprednisolone (1 g) or oral prednisone (1,250 mg) in 21 patients with MS. A triple sugar test solution was consumed at bedtime, and urine was collected overnight. Urine sugar concentrations were determined by high-pressure liquid chromatography. Gastric permeability was expressed as total mg of sucrose excreted.

RESULTS: Seventeen patients completed the protocol (12 oral, 5 IV). Baseline sucrose excretion was normal in all. Both groups demonstrated an increase in gastric permeability after steroid treatment, but there was no difference between the two groups (95% CI 95 to 91 mg, p = 0.96). After treatment, three (25%) patients in the oral group, and two (40%) patients the IV group, had modestly abnormal gastric permeability (95% CI 34 to 64%, P = 0.6).

CONCLUSIONS: Short-term high-dose oral prednisone is not associated with greater gastric damage, as measured with permeability tests, than IV methylprednisolone. High-dose oral prednisone should be considered a first-line treatment option for MS attacks.

Key words: Corticosteroids—MS—Gastric permeability—Peptic ulcer disease.




This article has been cited by other articles:


Home page
 NeurologyHome page
V. Martinelli, M. A. Rocca, P. Annovazzi, A. Pulizzi, M. Rodegher, F. M. Boneschi, R. Scotti, A. Falini, M. P. Sormani, G. Comi, et al.
A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS
Neurology, December 1, 2009; 73(22): 1842 - 1848.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Strupp and L. M. Metz
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis
Neurology, March 22, 2005; 64(6): 1100 - 1100.
[Full Text] [PDF]

Home page
 NeurologyHome page
September 28 Highlight and Commentary
Neurology, September 28, 2004; 63(6): 945 - 945.
[Full Text] [PDF]

Home page
 NeurologyHome page
S. A. Morrow, C. A. Stoian, J. Dmitrovic, S. C. Chan, and L. M. Metz
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis
Neurology, September 28, 2004; 63(6): 1079 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. A. Calabresi
Considerations in the treatment of relapsing-remitting multiple sclerosis
Neurology, April 23, 2002; 58(90084): S10 - 22.
[Abstract] [Full Text]